Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial.
Sun SunHåkan JonssonKlas-Göran SahlènMats AndénLars BeckmanPer FranssonPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)
The current study did not support that the ultra-hypo-fractionated treatment was more cost-effective than the conventional fraction treatment up to the sixth year of the trial.